The new campaign stars former NFL quarterback Alex Smith, whose leg injury during a 2018 game led to a case of ...

Vertex Pharmaceuticals is expected to outshine projections when it reports Q1 2025 earnings, with strong sales from its ...

New non-opioid pain killer get FDA approval for acute pain. Patients are taking note. Also demonstrated efficacy, just not ...

Vertex Pharmaceuticals got a healthy boost on Tuesday, with shares climbing nearly 3% thanks to a double dose of analyst ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Casgevy, approved in 2023, is a medicine for two rare, life-threatening blood disorders with few treatment options. Journavx ...

On Jan. 30, the United States Food and Drug Administration made a potentially revolutionary decision to approve Vertex Pharmaceuticals’ new pain relief medication marketed under the name Journavx.

Vertex remains focused on diversifying its product portfolio and recently launched two new approved therapies: Alyftrek and Journavx. Alyfrtek is an improvement to VRTX’s CF portfolio ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

As per the analyst, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s recently-approved NaV1.8 inhibitor, JOURNAVX, can gain significant traction in the outpatient setting. Notably ...

Casgevy and Journavx are poised to become significant growth drivers for Vertex Pharmaceuticals in the coming years, marking pivotal steps in the company's push to diversify its portfolio. With ...